John Richard Pinion, Executive Vice President and Chief Quality Operations Officer at Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), sold 10,029 shares of the company’s common stock on March 2, 2026, generating proceeds of approximately $228,661. The shares changed hands at prices between $22.54 and $23.11.
The share sale follows a conversion event: on March 1, 2026, Pinion had 11,137 performance stock units converted into common stock, recorded with a value of $0. After completing the March 2 sale, Pinion’s direct holdings in Ultragenyx total 110,026 shares. That total includes 490 shares acquired under the company’s Amended and Restated Employee Stock Purchase Plan on April 30, 2025, and previously disclosed common stock underlying restricted stock units that remain subject to vesting conditions.
Ultragenyx’s market price at the time of reporting was $22.07, which is 48% below its 52-week high of $42.37. An InvestingPro analysis noted in the company’s filing suggests the shares may be undervalued at current levels, though the stock has clearly retraced substantially from its year-ago peak.
From an operational and financial perspective, the company faces notable near-term profitability challenges. According to InvestingPro Tips cited in related disclosures, analysts do not expect Ultragenyx to be profitable during the current year. The firm’s fourth-quarter 2025 results reflect a mixed financial picture: revenue of $207 million exceeded the forecast of $192.15 million, a 7.73% positive surprise, while diluted earnings per share came in at negative $1.29 versus an anticipated negative $1.15, missing estimates.
Regulatory progress remains a material development for the company. The U.S. Food and Drug Administration has accepted Ultragenyx’s Biologics License Application for DTX401, an AAV gene therapy intended to treat Glycogen Storage Disease Type Ia, and granted the application Priority Review. The FDA set an action date for this filing of August 23, 2026. The submission positions the therapy as a potential treatment aimed at the underlying cause of the disorder, subject to the agency’s review and final decision.
On the analyst front, Canaccord Genuity adjusted its valuation stance on Ultragenyx following the fourth-quarter report and the company’s restructuring plans. Canaccord lowered its price target to $79 from $128 while retaining a Buy rating. The firm cited concerns arising from the quarter’s results and the scope of the restructuring in explaining the target revision.
The transactions and recent corporate updates - an insider sale after a conversion event, a mixed earnings report, regulatory progress on a late-stage therapy, and an analyst price-target reset - together provide market participants with several data points to consider when evaluating Ultragenyx’s near-term outlook.